Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line

Phase IV Study on QoL in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01430546

Enrollment

133

Registered

2011-09-08

Start date

2010-11-30

Completion date

Unknown

Last updated

2016-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Relapsed and Refractory Multiple Myeloma

Brief summary

The purpose of this study is to quantify the burden of treatment in relapsed or refractory multiple myeloma in patients receiving lenalidomide after one prior treatment for myeloma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Be at least 18 years of age 2. Have a confirmed diagnosis of MM 3. Starting lenalidomide treatment for MM (due to relapsed or refractory disease) after one prior treatment. 4. Have personally signed and dated a legally effective written informed consent form prior to admission to the study. 5. Must be willing and able to understand and comply with the study requirements.

Exclusion criteria

1. Individuals who have taken any experimental drugs or participated in a clinical trial within 30 days prior to screening. 2. Individuals with significant psychiatric illness or a clinically significant acute/chronic uncontrolled medical condition that might affect their experience of myeloma symptoms or their ability to describe them.

Countries

Sweden

Outcome results